Axitinib in Metastatic Renal Cell Carcinoma
Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar con...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Healthcare Communications
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873008/ |